Costs of expensive new drugs threaten financial sustainability of NHS

Costs of expensive new drugs threaten financial sustainability of NHS New figures show that the total cost of prescription medicines to the NHS in England reached a new high of £17.2 billion in the financial year 2021 –2022, according to a new independent report.

The report, from a team at the University of York, the London School of Economics and Political Science (LSE), and the London School of Hygiene & Tropical Medicine (LSHTM), shows that since 2018 NHS spending on branded medicines has been increasing by over five per cent annually - this excludes expenditure on COVID-19 vaccines and treatments.

See also:

• Costs of expensive new drugs threaten financial sustainability of NHS while pharma industry lobbies for increase on medicines spending London School of Economics and Political Science